Osteopontin – a new marker in neoplastic diseases

Jolanta Mrochem; Wiesława Bartnik

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

8/2008
vol. 12

Send email

Copy url:

abstract:

Osteopontin – a new marker in neoplastic diseases

Jolanta Mrochem

,

Wiesława Bartnik

Współczesna Onkologia (2008) vol. 12; 8 (349–353)

Online publish date: 2008/12/05

View full text Get citation

The molecule, currently known as osteopontin (OPN) was first described in 1979 as a phosphoprotein associated with transformation of epithelial cells. Identification of its role in osteoblasts, in 1986, as a calcium binding protein, enabling formation of bone structure, contributed to it becoming widely known as osteopontin. Osteopontin is overexpressed in various physiological and pathological processes, as for instance: bone remodeling, inflammation, atherosclerosis, vascular injury and renal diseases. Numerous publications suggest that OPN can be a valuable tool in clinical oncology for prognosis of disease deve-lopment and treatment monitoring of a variety of cancers. Recent reports on the role of osteopontin in mechanisms involved in progression of cancer indicate that OPN may be considered as
a potential target for chemotherapy.

keywords:

Osteopontin – a new marker in neoplastic diseases

Jolanta Mrochem , Wiesława Bartnik

osteopontin, progression of cancer

Jolanta Mrochem

,

Wiesława Bartnik